Comparative Pharmacology
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENETRON versus PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE.
PHENETRON vs PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic, and sedative. Dextromethorphan is a cough suppressant that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
Adults: 50 mg intramuscularly every 6 hours as needed.
For cough and upper respiratory symptoms: 5 mL (containing promethazine hydrochloride 6.25 mg and dextromethorphan hydrobromide 15 mg) orally every 4 to 6 hours, not to exceed 30 mL in 24 hours.
None Documented
None Documented
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Promethazine: 10-19 hours (mean 12 hours). Dextromethorphan: extensive metabolizers (CYP2D6) 3-5 hours; poor metabolizers 20-30 hours. Clinical context: accumulation with repeated dosing, especially in poor metabolizers.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Promethazine: primarily hepatic metabolism, renal excretion of metabolites (~70%, <1% unchanged); fecal excretion (20-30%). Dextromethorphan: hepatic metabolism, renal excretion of metabolites and <1% unchanged drug.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic